File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Stem cells for myocardial repair

TitleStem cells for myocardial repair
Authors
KeywordsCardiology
Ischaemic heart disease
Stem cells
Issue Date2010
PublisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com
Citation
Thrombosis And Haemostasis, 2010, v. 104 n. 1, p. 6-12 How to Cite?
AbstractThere is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy. © Schattauer 2010.
Persistent Identifierhttp://hdl.handle.net/10722/125015
ISSN
2015 Impact Factor: 5.255
2015 SCImago Journal Rankings: 2.089
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Research Grant CouncilHKU 763306M
HKU 7747/08M
CC Wong Stem Cell Fund
Funding Information:

This work was supported by grants the Hong Kong Research Grant Council General Research Fund (HKU 763306M, HKU 7747/08M to C.W.S. and H.F.T.) and the CC Wong Stem Cell Fund (to H.F.T.).

References

 

DC FieldValueLanguage
dc.contributor.authorSiu, CWen_HK
dc.contributor.authorLiao, SYen_HK
dc.contributor.authorLiu, Yen_HK
dc.contributor.authorLian, Qen_HK
dc.contributor.authorTse, HFen_HK
dc.date.accessioned2010-10-31T11:06:43Z-
dc.date.available2010-10-31T11:06:43Z-
dc.date.issued2010en_HK
dc.identifier.citationThrombosis And Haemostasis, 2010, v. 104 n. 1, p. 6-12en_HK
dc.identifier.issn0340-6245en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125015-
dc.description.abstractThere is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy. © Schattauer 2010.en_HK
dc.languageengen_HK
dc.publisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.comen_HK
dc.relation.ispartofThrombosis and Haemostasisen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectCardiologyen_HK
dc.subjectIschaemic heart diseaseen_HK
dc.subjectStem cellsen_HK
dc.subject.meshBone Marrow Cells - pathology-
dc.subject.meshMyoblasts, Skeletal - pathology-
dc.subject.meshMyocardial Infarction - pathology - physiopathology - therapy-
dc.subject.meshMyocardium - metabolism - pathology-
dc.subject.meshStem Cell Transplantation-
dc.titleStem cells for myocardial repairen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0340-6245&volume=104&issue=1&spage=6&epage=12&date=2010&atitle=Stem+cells+for+myocardial+repairen_HK
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_HK
dc.identifier.emailLian, Q:qzlian@hkucc.hku.hken_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authoritySiu, CW=rp00534en_HK
dc.identifier.authorityLian, Q=rp00267en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1160/TH09-05-0336en_HK
dc.identifier.pmid20352151-
dc.identifier.scopuseid_2-s2.0-77954375976en_HK
dc.identifier.hkuros173516en_HK
dc.identifier.hkuros182864-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77954375976&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume104en_HK
dc.identifier.issue1en_HK
dc.identifier.spage6en_HK
dc.identifier.epage12en_HK
dc.identifier.isiWOS:000280298300003-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridSiu, CW=7006550690en_HK
dc.identifier.scopusauthoridLiao, SY=22433820700en_HK
dc.identifier.scopusauthoridLiu, Y=36071722500en_HK
dc.identifier.scopusauthoridLian, Q=7003399023en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats